Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
← catalyst calendarNCT06334133 · readout ≤ 254 d
Sponsored by vTv Therapeutics (industry) · VTVT — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
150estimated
Sites
52
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-14 | actual | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 1
Interventions
- Drug: Cadisegliatin 800 mg QD — also filed as TTP399
- Drug: Cadisegliatin 800 mg BID — also filed as TTP399
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange in incidence of Level 2 or Level 3 hypoglycemia
measured 26 weeks
Permalink · VTVT's whole pipeline · Catalyst calendar · Every registered study · What changed